Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium

On November 18, 2026 Iambic (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, reported two preclinical poster presentations at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), known as the Triple Meeting, taking place November 18–20, 2026 in Barcelona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The posters present preclinical data for IAM-C1, a selective dual CDK2/4 inhibitor in development for HR+/HER2- breast cancer and CCNE1-amplified cancers, and IAM217, a brain-penetrant KIF18A inhibitor in development for cancers with chromosomal instability (CIN). Both wholly owned drug development candidates were designed using Iambic’s molecular superintelligence platform, which integrates Enchant and NeuralPLexer, its flagship AI technologies for multimodal endpoint and protein-ligand structural predictions, with automated chemistry and biology experimentation.

"IAM-C1 and IAM217 are Iambic’s second and third drug development candidates and demonstrate what our molecular superintelligence platform is designed to do: discover and advance differentiated molecules to address urgent unmet patient need," said Tom Miller, PhD, Co-Founder and CEO, Iambic. "For IAM-C1, it meant dual CDK2 and CDK4 activity while sparing other CDKs associated with dose-limiting toxicities. For IAM217, it meant selective KIF18A inhibition with brain penetrance. The preclinical data presented at ENA reflect both design goals, and we look forward to advancing these programs to and through clinic."

"Resistance to CDK4/6 inhibitors remains a key limitation in HR+/HER2- breast cancer, and increased CDK2 signaling through cyclin E is one route to that resistance," said Pete Olson, PhD, Chief Scientific Officer, Iambic. "In our studies, IAM-C1 was active in models driven by CDK2, CDK4 or both, including a patient-derived model from a patient previously treated with abemaciclib and palbociclib. With IAM217, we saw selective activity against chromosomally unstable tumor cells in vitro and deep regressions in vivo, including in an intracranial model. We are encouraged by these preclinical data and look forward to submitting an IND for IAM-C1 later this year and initiating the Phase 1/2 trial for IAM217."

POSTER PRESENTATIONS

Title: IAM-C1, a Potent and Selective Dual CDK2/CDK4 Inhibitor, Demonstrates Robust Antitumor Activity and a Favorable Preclinical Tolerability Profile
Abstract: 234 | Poster: PB-129 | Session: Molecular Targeted Agents | November 19, 2026 | Exhibition Hall, CCIB| Presenter: Pete Olson, Iambic

Summary:

IAM-C1 inhibited CDK2/cyclin E1 and CDK4/cyclin D1 with biochemical IC50 values below 1 nM. Across a broad kinome panel at 30 nM, four non-mutant off-target kinases met the binding-hit criterion.
In cancer cell lines with distinct CDK dependencies (MCF-7, CDK4; OVCAR-3, CDK2; MFE-296, CDK2/CDK4), IAM-C1 suppressed RB phosphorylation (IC50 18–19 nM), inhibited proliferation (IC50 40–100 nM) and depleted S-phase cells.
As a single agent, IAM-C1 achieved tumor growth inhibition (TGI) of 138% in MCF-7, 97% in OVCAR-3 and 94% in MFE-296 xenograft models. In the CDK2/CDK4 co-dependent MFE-296 model, TGI with IAM-C1 exceeded that of single-agent CDK2, CDK4 and CDK4/6 inhibitors and was comparable to a combination of selective CDK2 and CDK4 inhibitors.In the ST4316B ER+/HER2- breast cancer patient-derived xenograft model, established from a patient previously treated with abemaciclib and palbociclib, IAM-C1 achieved 78% TGI versus 24% with palbociclib.
In the MCF-7 model, IAM-C1 combined with fulvestrant or imlunestrant produced significantly greater antitumor activity than either selective estrogen receptor degrader alone.
In rats, IAM-C1 reduced neutrophil counts by a mean of 13% at exposure multiples of 1.3–1.4x across two studies, compared with 48% for combined selective CDK2 and CDK4 inhibitors at 0.65–0.75x and 69% for palbociclib.

Title: IAM217: a Novel, Brain-penetrant KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer
Abstract: 330 | Poster: PB-122 | Session: New Drugs | November 20, 2026 | Exhibition Hall, CCIB | Presenter: Jill Hallin, Iambic

Summary:

IAM217 inhibited growth of CIN-high OVCAR-3 ovarian cancer cells (IC50 24 nM) while sparing CIN-low MCF-7 cells (IC50 >10,000 nM) and bone marrow hematopoietic progenitor cells (IC50 7,700 nM to >10,000 nM). Anti-proliferative activity tracked with mitotic arrest.
IAM217 was negative in a mini-Ames assay, showed a clean kinesin and kinome selectivity screen, and achieved CNS exposure in rodents.
Once-daily oral dosing in ovarian cancer xenograft models produced dose-dependent plasma and tumor exposure that correlated with dose-dependent tumor growth inhibition and modulation of the mitotic marker phospho-histone H3. IAM217 was well tolerated at all dose levels tested.
At 60 mg/kg once daily for approximately 21 days, IAM217 showed antitumor activity across a panel of breast cancer cell line-derived and patient-derived xenograft models, as well as ovarian, colon and osteosarcoma models, with deep regressions in multiple models.
In an intracranial JIMT-1 breast cancer model of brain metastasis, IAM217 achieved approximately 90% regression. Unbound plasma and cerebrospinal fluid concentrations exceeded the free IC90 for more than 24 hours.
In vitro, IAM217 combined with eribulin showed synergy in Kuramochi (ovarian cancer) and HCC1187 (triple-negative breast cancer) cell lines.

(Press release, Iambic Therapeutics, NOV 18, 2026, View Source [SID1234674941])

Grant of Restricted Stock Units and Warrants to Employees in Genmab

On November 18, 2026 Genmab A/S (Nasdaq: GMAB) reported that the Board of Directors decided to grant 4,993 restricted stock units and 4,607 warrants to employees of the Company and the Company’s subsidiaries.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 3,496.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units.

The exercise price for each warrant is DKK 3,496. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 1,230.13.

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the Board of Directors on February 23, 2021. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Governance > Compensation > Warrants.

(Press release, Genmab, NOV 18, 2026, View Source [SID1234674910])

Verismo Therapeutics Licenses In Vivo CAR T Engineering Technology to Extend Its Novel Multi-Chain KIR-CAR Platform

On November 18, 2026 Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, reported that the company licensed the PACK-IT technology enabling in vivo engineering of KIR-CAR T cells from Stanford Medicine. The new licensing agreement provides Verismo with breakthrough technology from the lab of Crystal Mackall, MD, Ernest and Amelia Gallo Family Professor and professor of pediatrics and medicine at Stanford Medicine and founding director of the Stanford Center for Cancer Cell Therapy. The agreement will allow Verismo to extend its multi-chain KIR-CAR platform into next-generation in vivo delivery of KIR-CAR T cell therapies, with the potential to reduce time-to-treatment and cost and broaden patient access over time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Verismo’s multi-chain KIR-CAR platform is designed to take CAR T therapy beyond the single-chain limitations of current approaches, with the potential to deliver durable anti-tumor responses while minimizing off-target toxicity. The platform is currently advancing in two Phase 1 clinical trials — SynKIR-110 (NCT05568680) in solid tumors and SynKIR-310 (NCT06544265) in B-cell malignancies. Both trials have generated early positive signals presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2026 Annual Meeting: initial STAR-101 data for SynKIR-110 showed a positive safety profile with dose-dependent efficacy signals and no dose-limiting toxicities; initial CELESTIAL-301 data for SynKIR-310 included a complete response in a follicular lymphoma patient at the lowest dose level, sustained beyond six months.

"Our KIR-CAR platform is at the center of everything Verismo is building — designed to take CAR T beyond its current limitations by delivering a durable anti-tumor response while minimizing off-target toxicity," said Bryan Kim, CEO and Co-Founder of Verismo Therapeutics. "Today, KIR-CAR is advancing along the established CAR T pathway in two Phase 1 clinical trials, and adding the PACK-IT technology is intended to extend the platform into next-generation, off-the-shelf in vivo delivery — realizing the full potential of KIR-CAR to reach more patients, faster, and at lower cost."

Approved CAR T therapies are engineered using ex vivo manufacturing — a personalized approach in which each patient’s cells are collected, engineered, expanded, and quality-tested in a facility over a period of weeks before being returned to the patient. This lengthy, well-characterized process has enabled the current generation of approved CAR T therapies, but its complexity can limit patient access and increase cost.

By contrast, the licensed Programmable Antigen-Mediated Cellular Knock-in of T cell (PACK-IT) platform is a versatile CAR T engineering technology that uses engineered T cell-targeted lentiviral particles to deliver CAR genes directly to T cells, and can be deployed either in vivo, to reprogram a patient’s own T cells in the body, or ex vivo, in an accelerated ex vivo workflow. In preclinical data published at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2025 Annual Meeting, PACK-IT generated CAR T cells with superior potency compared to conventional lentivirus, and enabled in vivo generation of CD19-CAR T cells capable of controlling leukemia in preclinical models.¹ Verismo intends to apply PACK-IT primarily in an off-the-shelf, in vivo configuration — compressing the multi-week ex vivo manufacturing workflow into a same-day in vivo step with the potential to lower cost, shorten time to treatment, and improve patient access over time.

About the KIR-CAR Platform

The KIR-CAR platform is a multi-chain T cell therapy that has shown highly effective solid tumor treatment in otherwise CAR-resistant animal models with hard-to-treat tumors. Using NK cell-derived killer immunoglobulin-like receptor (KIR) and DAP12 to split the target binding and T cell activation signals provides a novel paired immune-receptor activation that is independent from CD3 signaling and works independently of co-stimulation. KIR-CAR enables sustained cell receptor expression in T cells, and induces deeper, more durable tumor treatments. Together, this multi-chain cell signaling platform provides the potential to deliver effective patient treatments by eliminating the constant background activation and early T cell exhaustion observed in conventional single-chain CAR T therapy, with potential to treat patients with both solid and hematologic tumors.

(Press release, Verismo Therapeutics, NOV 18, 2026, View Source [SID1234674926])

Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026

On November 18, 2026 Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported that its next-generation sequencing (NGS)-based clonoSEQ test for measurable residual disease (MRD) assessment will be featured in approximately 100 abstracts, including 27 oral presentations, at the 68th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper), taking place Dec. 12–15, 2026, in New Orleans.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research at this year’s meeting reflects the continued evolution of MRD assessment across hematologic malignancies, moving beyond measuring the depth of treatment response to informing how therapies are developed, evaluated, and adapted based on individual patient response. Across 20 unique biopharma-sponsored studies featuring clonoSEQ, MRD is utilized as a primary endpoint in four studies and a secondary endpoint in 11, underscoring how highly sensitive MRD assessment has become integral to evaluating therapeutic efficacy and advancing new treatment approaches.

Key highlights include:

Advancing MRD-informed treatment strategies in multiple myeloma: At ASH (Free ASH Whitepaper), data from pivotal Phase 3 studies, including PERSEUS, AURIGA, and BENEFIT, reinforce clonoSEQ’s established role in evaluating treatment response, while research from PERSEUS and IMMUNOPLANT highlights its use in informing treatment strategies, including maintenance de-escalation and consolidation therapy. Additionally, real-world research from the Icahn School of Medicine at Mount Sinai leveraging clonoSEQ data identifies patients with sustained MRD negativity and survival comparable to the general population, highlighting the ability to inform treatment discontinuation and providing new evidence supporting the possibility of cure in multiple myeloma.
Evaluating MRD-guided treatment in chronic lymphocytic leukemia (CLL): Several studies, including the Phase 3 MAJIC study, demonstrate the use of clonoSEQ in guiding the duration of therapy and assessing response. In addition, in the MIRACLE study, MRD is also used as a primary endpoint.
Strengthening MRD testing utility relative to PET/CT in lymphoma: New real-world data from Adaptive, Hackensack University Medical Center, and the University of Nebraska Medical Center, as well as study data from Wilmot Cancer Center, show the prognostic value of clonoSEQ MRD assessment following frontline treatment in diffuse large B-cell lymphoma (DLBCL), including its ability to complement imaging.

"The research being presented at ASH (Free ASH Whitepaper) underscores clonoSEQ’s established position in pivotal clinical trials and showcases its ever-expanding role as a tool to inform patient care strategies across blood cancers," said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. "Multiple myeloma offers a powerful example of this progress, with updated clinical guidelines, a new definition of cure, and important Phase 3 research reinforcing the value of systematic MRD assessment. With a strong foundation of clinical evidence, regulatory validation and unparalleled real-world patient experience, Adaptive is helping shape the future of MRD-guided care for blood cancer patients."

A list of selected abstracts featuring clonoSEQ is available here.

About clonoSEQ
clonoSEQ is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), T-cell acute lymphoblastic leukemia (T-ALL), and other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.

clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier.

clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request. To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

(Press release, Adaptive Biotechnologies, NOV 18, 2026, View Source [SID1234674942])

Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer

On November 18, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported compelling preclinical data that supports expanding the clinical development of atebimetinib, its investigational deep cyclic MEK inhibitor, to a third tumor type: anaplastic thyroid cancer (ATC). The findings were presented at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The preclinical data demonstrate broad anti-tumor activity for atebimetinib across genetically diverse ATC models, enhanced chemotherapy potency in vitro, and superior tumor control with atebimetinib plus chemotherapy compared with chemotherapy or standard targeted therapy alone in an animal model of ATC.

These findings provide important scientific support for Immuneering’s recently announced Phase 2 clinical program evaluating atebimetinib in patients with ATC, an aggressive malignancy with limited treatment options and a five-year survival rate of less than 10%.

"We are very excited to expand the development of atebimetinib to a third tumor type, for patients with anaplastic thyroid cancer," said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering Corporation. "In first-line pancreatic cancer patients, we reported compelling data at ASCO (Free ASCO Whitepaper) for atebimetinib+chemo, including long survival and an excellent tolerability profile in an all-comers population, and are excited to share another update on that trial in 1H 2027. Enthusiasm is high for our Phase 3 MAPKeeper 301 trial of atebimetinib+chemo in first line pancreatic cancer patients, which is enrolling ahead of schedule, and we are preparing to dose the first patient in our Phase 2 study of atebimetinib+anti-PD-1 in first-line RAS mutant lung cancer by the end of the year. This incredible momentum gives us the opportunity to serve more patients, and the preclinical data we reported makes it clear that running a Phase 2 study of atebimetinib+chemotherapy in anaplastic thyroid cancer is an important next step for atebimetinib. We observed activity across a broad range of ATC models, including those with different underlying genetic drivers, and importantly, we saw that adding atebimetinib to chemotherapy produced substantially greater tumor control than either chemotherapy or established targeted therapy alone in our preclinical model, including following progression on targeted therapy. These results reinforce our confidence in the scientific rationale for the Phase 2 ATC program we announced last week and underscore the potential of atebimetinib to help a broad and expanding set of cancer patients."

Broad anti-tumor activity across genetically diverse ATC models

Atebimetinib demonstrated dose-dependent inhibition of tumor cell proliferation across all nine ATC cell lines evaluated, including models harboring BRAF V600E mutations, RAS mutations and no identified MAPK pathway alteration.
Six of the nine ATC cell lines demonstrated sensitivity to atebimetinib at concentrations below the free-drug maximum plasma concentrations achieved in patients at clinically evaluated doses.
These findings suggest that atebimetinib’s potential utility in ATC may extend beyond patients with BRAF V600E mutations, who currently have access to targeted BRAF/MEK inhibitor therapy.

Enhanced chemotherapy potency across multiple treatment combinations

The addition of atebimetinib increased the potency of three chemotherapy agents commonly used in ATC – pemetrexed, carboplatin and paclitaxel – reducing the concentrations required to inhibit tumor cell proliferation in most ATC cell lines evaluated.
These findings are consistent with the proposed mechanism of atebimetinib, which is designed to deliver deep cyclic inhibition of MEK signaling, potentially limiting the adaptive MAPK pathway reactivation that can enable tumor cells to survive chemotherapy.
Superior tumor control in an ATC animal model, including following targeted therapy

In an ongoing BRAF V600E-mutant ATC xenograft study, atebimetinib combined with carboplatin and pemetrexed demonstrated superior tumor control compared with chemotherapy alone or the targeted therapy combination of dabrafenib and trametinib.
Importantly, the atebimetinib combination also demonstrated tumor control when administered following prior treatment with dabrafenib and trametinib, supporting its potential utility in patients whose disease has progressed following targeted therapy.
All treatment regimens evaluated in the study were reported to be well tolerated. The study remains ongoing, with additional treatment groups and durability data expected.

Addressing a Significant Unmet Medical Need in ATC

Anaplastic thyroid cancer is one of the most aggressive and lethal solid tumors, with a five-year survival rate of less than 10%. Despite advances in targeted therapy for patients with BRAF V600E-mutant disease, treatment options remain limited, particularly following disease progression and for patients without this mutation.

Analysis of genomic data from 379 patients with ATC in AACR (Free AACR Whitepaper) Project GENIE found that approximately 78% had an alteration involving the MAPK signaling pathway, highlighting the importance of this pathway in ATC biology.

Atebimetinib’s deep cyclic MEK inhibition is designed to disrupt oncogenic MAPK signaling while allowing recovery of normal cells between doses. Immuneering believes this differentiated approach may enable atebimetinib to enhance the anti-tumor effects of chemotherapy while potentially overcoming limitations associated with conventional chronic MEK inhibition.

The preclinical findings presented today support Immuneering’s planned Phase 2 clinical trial of atebimetinib plus chemotherapy in second-line ATC, including patients with BRAF V600E-mutant disease previously treated with targeted therapy and patients with non-V600E disease.

Poster Presentation Details:
Title: Atebimetinib, a deep cyclic inhibitor of MEK, combined with chemotherapy: preclinical rationale for treatment of anaplastic thyroid cancer (ATC).
Abstract Number: 144
Poster Number: PB-144
Presenter: Praveen Nair
Date: Wednesday, November 18, 2026

The poster is available on the publications section of Immuneering’s website.

About Atebimetinib

Atebimetinib is the first in a new category of oral drug candidates, Deep Cyclic Inhibitors (DCIs), designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Each of these mechanisms has been well established to improve survival in published studies. DCIs challenge the conventional model of sustained or continuous inhibition in oncology. Whereas most therapies are designed for sustained inhibition, driving cancer to adapt and develop resistance so tumors shrink quickly but temporarily, DCIs are designed to pulse faster than tumors can adapt, so tumors shrink slowly but durably. Moreover, DCIs aim to restore full transient signaling to healthy cells, with the goal of leading to fewer adverse events. Atebimetinib targets MEK, a key control point in the MAPK pathway (RAS-RAF-MEK-ERK), which is pathologically activated in a majority of cancers, including approximately 97% of pancreatic cancers. Targeting MEK blocks a broader range of MAPK pathway alterations because it is further downstream, creating the potential for more durable benefit.

(Press release, Immuneering, NOV 18, 2026, View Source [SID1234674911])